419 followers
RT @CCR_AACR: ctDNA-based minimal residual diseases assessment is a promising method to complement cell-based approaches, e.g. #FlowCytomet…
287 followers
RT @CCR_AACR: ctDNA-based minimal residual diseases assessment is a promising method to complement cell-based approaches, e.g. #FlowCytomet…
4,376 followers
ctDNA-based minimal residual diseases assessment is a promising method to complement cell-based approaches, e.g. #FlowCytometry in #ChronicLymphocyticLeukemia patients treated with obinutuzumab, acalabrutinib and venetoclax. https://t.co/bDOvQozWQ5 @Halle
67 followers
Circulating tumor DNA-based MRD assessment in patients with CLL treated with obinutuzumab, acalabrutinib and venetoclax | Clinical Cancer Research | American Association for Cancer Research https://t.co/hF5gYJGET7